Rock Out like It’s the 00s
    Listen Now

    Listen to Stations For You

    Change genre preferences

  • Cart 0
  • | Register
  • .
    ' } ); ss.positionArrowsIa('#dyn-ss-1', 0, slideshow_length); /* Attach event handlers */ $('#dyn-ss-1').find('.controls.primary .prev').on('click tap', function(event) { currSlide = slideshowInst.getCurrentSlide(); event.preventDefault(); if(currSlide !== 0){ slideshowInst.goToPrevSlide(); if( thisDevice === "mobile" ) { webmd.metrics.dpv({ moduleName: 'ia-ss-ctl_prev', pageName: window.s_pagename, iCount: currSlide, refresh: false }); } else { wmdPageLink('ia-ss-ctl_prev'); } } }); $('#dyn-ss-1').find('.controls.primary .next').on('click tap', function(event) { event.preventDefault(); slideshowInst.goToNextSlide(); currSlide = slideshowInst.getCurrentSlide() + 1; if( thisDevice === "mobile" ) { webmd.metrics.dpv({ moduleName: 'ia-ss-ctl_next', pageName: window.s_pagename, iCount: currSlide, refresh: false }); } else { wmdPageLink('ia-ss-ctl_next'); } }); /* Reposition arrows when browser is resized */ $(window).on('resize', function() { var currentSlide = slideshowInst.getCurrentSlide(); // only run if width changed to prevent it triggering on iPhone scroll if (currentWidth !== $(window).width()) { currentWidth = $(window).width(); ss.positionArrowsIa('#dyn-ss-1', currentSlide, slideshow_length); } }); }, onSlideAfter: function ($slideElement, oldIndex, newIndex) { ss.positionArrowsIa('#dyn-ss-1', newIndex, slideshow_length); } } ); }); }); });

    "Because the chemo is inside the red blood cell, there is less exposure,'' she says. And that should translate to less toxicity, she says.

    Erytech Pharma in Lyon, France, developed the treatment and funded the study. EryDel, an Italian company, is working on a superblood treatment, EryDex, for the rare genetic disease ataxia telangiectasia (AT). AT starts in childhood and causes neurological problems such as balance issues, problems with motor skills and the immune system, and respiratory infections. Patients can lose the ability to write and talk and walk normally. Many patients die in their 20s.

    EryDex loads a steroid drug into red blood cells, then gives it to patients through an IV once a month. More than 200 people have been given the treatment, says Luca Benatti, PhD, EryDel's CEO.

    .
    .
    NEWSLETTER SIGN UP
    .
    .
    .